3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
8
Lung Neoplasms
3
Multiple Myeloma
2
Carcinoma
2
Recurrence
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Breast Neoplasms
1
Adenocarcinoma of Lung
1
Interventions
Oxaliplatin
49
Fluorouracil
45
Leucovorin
42
Capecitabine
40
Irinotecan
31
Bevacizumab
31
Radiotherapy
24
Cetuximab
23
Radiation
13
Panitumumab
13
Folfox protocol
10
Surgical Procedures, Operative
9
IFL protocol
8
Radiotherapy, Intensity-Modulated
6
Magnetic Resonance Spectroscopy
6
aflibercept
5
Immunohistochemistry
5
Gene Expression Profiling
5
Chemotherapy, Adjuvant
5
Fluorodeoxyglucose F18
4
Floxuridine
4
Celecoxib
4
trifluridine tipiracil drug combination
3
dehydroftorafur
3
XELOX
3
Sorafenib
3
Ramucirumab
3
Neoadjuvant Therapy
3
Erlotinib Hydrochloride
3
Drug Therapy
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Rectal Neoplasms
×
L-BLP25
×
Clear all
NCT01507103
2017-01-13
SPRINT
Merck KGaA, Darmstadt, Germany
Phase 2
Completed
124 enrolled
9 charts